Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068541 | 1.00 | JAK3 (0.36) | JAK3TDP1EGFRITKGFER | |
| SCHEMBL23068542 | 1.00 | JAK3 (0.36) | JAK3TDP1EGFRITKGFER | |
| SCHEMBL23068546 | 0.93 | KMT2A (0.33) | JAK3TDP1EGFRJAK2ADORA3 | |
| SCHEMBL21061357 | 0.93 | KMT2A (0.33) | JAK3TDP1EGFRJAK2ADORA3 | |
| SCHEMBL23068547 | 0.93 | KMT2A (0.33) | JAK3TDP1EGFRJAK2ADORA3 | |
| SCHEMBL21098279 | 0.89 | JAK3 (0.41) | JAK3TDP1EGFRGFERJAK2 | |
| SCHEMBL21098275 | 0.89 | JAK3 (0.41) | JAK3TDP1EGFRGFERJAK2 | |
| SCHEMBL23084452 | 0.89 | JAK3 (0.41) | JAK3TDP1EGFRGFERJAK2 | |
| SCHEMBL29489171 | 0.89 | JAK3 (0.41) | JAK3TDP1EGFRGFERJAK2 | |
| SCHEMBL29489168 | 0.89 | JAK3 (0.41) | JAK3TDP1EGFRGFERJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| EP-3724194-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Leo Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115774-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | JAK3 2612/4885TDP1 46/4885EGFR 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.